Breaking News Instant updates and real-time market news.

TBPH

Theravance Biopharma

$24.44

1.07 (4.58%)

, JNJ

Johnson & Johnson

$131.83

1.44 (1.10%)

07:37
02/07/18
02/07
07:37
02/07/18
07:37

Theravance Biopharma and Janssen collaborating in development of TD-1473

Theravance Biopharma (TBPH) subsidiary Theravance Biopharma Ireland has entered into a global co-development and commercialization agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), for TD-1473 and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. Under the terms of the agreement, Theravance Biopharma will receive an upfront payment of $100M and will be eligible to receive up to an additional $900M in potential payments, if Janssen elects to remain in the collaboration following the completion of certain Phase 2 activities. Theravance Biopharma and Janssen will develop and commercialize TD-1473 in inflammatory intestinal diseases, with the two companies sharing profits in the US and expenses related to a potential Phase 3 program - 67% to Janssen; 33% to Theravance Biopharma -. Theravance Biopharma would receive double-digit tiered royalties on ex-US sales. TD-1473 is a novel, potent, orally administered pan-Janus kinase inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases. In 2018, Theravance Biopharma plans to initiate a large, Phase 2b/3 adaptive design induction and maintenance study in ulcerative colitis with TD-1473. The company is also now planning to initiate a Phase 2 study in Crohn's disease in 2018. Following completion of the Phase 2 Crohn's study and the Phase 2b induction portion of the ulcerative colitis study, Janssen can elect to enter into an exclusive license arrangement by paying Theravance Biopharma a fee of $200M. After Phase 2, Janssen would lead subsequent development of TD-1473 in Crohn's disease. Theravance Biopharma would be eligible to receive up to an additional $700M in development and commercialization milestone payments.

TBPH

Theravance Biopharma

$24.44

1.07 (4.58%)

JNJ

Johnson & Johnson

$131.83

1.44 (1.10%)

  • 12

    Feb

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 08

    Mar

  • 13

    Nov

TBPH Theravance Biopharma
$24.44

1.07 (4.58%)

03/29/17
PIPR
03/29/17
NO CHANGE
Target $42
PIPR
Overweight
Mylan news a positive for Theravance, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Mylan's (MYL) complete response letter for its generic version of GlaxoSmithKline's Advair "buys time and will likely preserve some pricing power in the broader respiratory space." This will be important for GSK's commercialization of the closed triple following potential regulatory approval at year end, Schimmer tells investors in a research note. This is also positive for Theravance Biopharma (TBPH), which stands to receive a "meaningful" mid/high single digit royalty on the closed triple, the analyst contends. He reiterates an Overweight rating on Theravance with a $42 price target. The stock is up 49c to $36.47 in afternoon trading.
05/10/17
LEER
05/10/17
NO CHANGE
Target $47
LEER
Outperform
Theravance Biopharma price target raised to $47 from $34 at Leerink
Leerink analyst Geoffrey Porges raised his price target Theravance Biopharma to $47 from $34 after the company reported Q1 financial results and provided an update for investors about its development progress and upcoming milestones. The analyst reiterates an Outperform rating on the shares.
06/16/17
CANT
06/16/17
INITIATION
Target $55
CANT
Overweight
Theravance Biopharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Theravance Biopharma with an Overweight rating and $55 price target.
08/16/17
EVER
08/16/17
INITIATION
Target $45
EVER
Outperform
Theravance Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Theravance Biopharma with an Outperform and a $45 price target.
JNJ Johnson & Johnson
$131.83

1.44 (1.10%)

01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.

TODAY'S FREE FLY STORIES

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

GE

General Electric

$15.05

0.2 (1.35%)

08:48
02/17/18
02/17
08:48
02/17/18
08:48
Periodicals
General Electric stock could drop another 10%, Barron's says »

General Electric lost $6B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

, VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

08:32
02/17/18
02/17
08:32
02/17/18
08:32
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

PWR

Quanta Services

$35.07

0.24 (0.69%)

EXP

Eagle Materials

$102.75

-3.83 (-3.59%)

FLR

Fluor

$57.63

-0.22 (-0.38%)

USCR

U.S. Concrete

$78.00

-1.4 (-1.76%)

ACM

Aecom

$35.36

0.08 (0.23%)

CBI

CB&I

$18.71

0.04 (0.21%)

GVA

Granite Construction

$60.36

2.69 (4.66%)

CAT

Caterpillar

$156.29

-3.69 (-2.31%)

MLM

Martin Marietta

$216.25

-6.34 (-2.85%)

V

Visa

$121.85

-0.43 (-0.35%)

AA

Alcoa

$47.36

-0.21 (-0.44%)

ARNC

Arconic

$25.36

0.14 (0.56%)

CENX

Century Aluminum

$24.12

1.85 (8.31%)

X

U.S. Steel

$44.75

5.76 (14.77%)

STLD

Steel Dynamics

$49.40

2.26 (4.79%)

AKS

AK Steel

$5.96

0.72 (13.74%)

CLF

Cleveland-Cliffs

$7.92

0.55 (7.46%)

NUE

Nucor

$68.54

2.96 (4.51%)

MT

ArcelorMittal

$36.48

1.19 (3.37%)

TKR

Timken

$45.00

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

  • 23

    May

  • 30

    May

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
Cambridge Healthtech Institute to hold a conference »

Molecular Med Tri-Con…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MIDD

Middleby

$135.00

1.94 (1.46%)

18:01
02/16/18
02/16
18:01
02/16/18
18:01
Hot Stocks
Middleby acquires Hinds-Bock Corporation, terms not disclosed »

Middleby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.14

0.14 (0.38%)

, TWX

Time Warner

$95.37

0.38 (0.40%)

17:37
02/16/18
02/16
17:37
02/16/18
17:37
Periodicals
Breaking Periodicals news story on AT&T, Time Warner »

Judge says to rule on …

T

AT&T

$37.14

0.14 (0.38%)

TWX

Time Warner

$95.37

0.38 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

CARS

Cars.com

$29.27

0.33 (1.14%)

17:31
02/16/18
02/16
17:31
02/16/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Cars.com »

Starboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONTX

Onconova

$1.07

0.01 (0.94%)

17:29
02/16/18
02/16
17:29
02/16/18
17:29
Hot Stocks
683 Capital reports 21.8% stake in Onconova, says shares undervalued »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$224.19

-1.21 (-0.54%)

17:26
02/16/18
02/16
17:26
02/16/18
17:26
Hot Stocks
General Dynamics awarded $148.9M government contract modification »

General Dynamics Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRS

Antares Pharma

$2.39

0.04 (1.70%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Antares Pharma »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$265.70

10.31 (4.04%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Huntington Ingalls awarded $1.43B government contract modification »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIT

AMCON Distributing

$87.50

0.13 (0.15%)

17:24
02/16/18
02/16
17:24
02/16/18
17:24
Hot Stocks
Breaking Hot Stocks news story on AMCON Distributing »

Hale Partnership reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$41.09

-0.76 (-1.82%)

, TSLA

Tesla

$335.49

1.425 (0.43%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Periodicals
Chevy Bolt sales bolstered by Tesla delays, tax credit worries, Reuters says »

Certain potential buyers…

GM

General Motors

$41.09

-0.76 (-1.82%)

TSLA

Tesla

$335.49

1.425 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AGN

Allergan

$164.04

-0.43 (-0.26%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Syndicate
Breaking Syndicate news story on Allergan »

Allergan files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 25

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.